Nasdaq · CIK 0001566044
YARW VYNE Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Jan 5, 2026. Close $19.71 on Oct 9, 2026, +113% from the 52-week low and -54% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
YARWOct 9, 2026 · close 19.71
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at VYNE Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 27Weak | Patrick G Lepore director buy | $44k 15,000 shares | +41% | - |
Transactions
The last 34 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | Mutya Harsch CHIEF LEGAL OFFICER AND GC | FTax withholding Common Stock | -3,579 | $0.58 | $2,076 | 125,905 | Jan 5, 2026 |
| Dec 31, 2025 | David Domzalski PRESIDENT AND CEO | FTax withholding Common Stock | -12,684 | $0.58 | $7,358 | 416,208 | Jan 5, 2026 |
| Dec 31, 2025 | Tyler Zeronda CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -7,858 | $0.58 | $4,558 | 103,795 | Jan 5, 2026 |
| Dec 31, 2025 | Iain Stuart CHIEF SCIENTIFIC OFFICER | FTax withholding Common Stock | -2,448 | $0.58 | $1,420 | 115,239 | Jan 5, 2026 |
| Dec 12, 2025 | Sharon Barbari director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 15, 2025 |
| Dec 12, 2025 | Steven L Basta director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 15, 2025 |
| Dec 12, 2025 | Patrick G Lepore director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 15, 2025 |
| Dec 12, 2025 | Elisabeth Sandoval Little director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 15, 2025 |
| Sep 30, 2025 | David Domzalski PRESIDENT AND CEO | FTax withholding Common Stock | -12,676 | $0.34 | $4,246 | 428,892 | Oct 2, 2025 |
| Sep 30, 2025 | Mutya Harsch CHIEF LEGAL OFFICER AND GC | FTax withholding Common Stock | -3,581 | $0.34 | $1,200 | 129,484 | Oct 2, 2025 |
| Sep 30, 2025 | Iain Stuart CHIEF SCIENTIFIC OFFICER | FTax withholding Common Stock | -2,453 | $0.34 | $822 | 117,687 | Oct 2, 2025 |
| Sep 30, 2025 | Tyler Zeronda CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -3,420 | $0.34 | $1,146 | 111,653 | Oct 2, 2025 |
| Jun 30, 2025 | David Domzalski PRESIDENT AND CEO | FTax withholding Common Stock | -12,676 | $1.65 | $21k | 441,568 | Jul 2, 2025 |
| Jun 30, 2025 | Mutya Harsch CHIEF LEGAL OFFICER AND GC | FTax withholding Common Stock | -3,581 | $1.65 | $5,909 | 133,065 | Jul 2, 2025 |
| Jun 30, 2025 | Iain Stuart CHIEF SCIENTIFIC OFFICER | FTax withholding Common Stock | -2,453 | $1.65 | $4,047 | 120,140 | Jul 2, 2025 |
| Jun 30, 2025 | Tyler Zeronda CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -3,420 | $1.65 | $5,643 | 115,073 | Jul 2, 2025 |
| Jun 2, 2025 | Mutya Harsch CHIEF LEGAL OFFICER AND GC | AGrant or award Common Stock | +1,145 | $0.81 | $927 | 136,646 | Jun 3, 2025 |
| Jun 2, 2025 | David Domzalski PRESIDENT AND CEO | AGrant or award Common Stock | +8,681 | $0.81 | $7,032 | 454,244 | Jun 3, 2025 |
| Mar 31, 2025 | David Domzalski PRESIDENT AND CEO | FTax withholding Common Stock | -30,498 | $1.58 | $48k | 445,563 | Apr 2, 2025 |
| Mar 31, 2025 | Mutya Harsch CHIEF LEGAL OFFICER AND GC | FTax withholding Common Stock | -8,828 | $1.58 | $14k | 135,501 | Apr 2, 2025 |
| Mar 31, 2025 | Iain Stuart CHIEF SCIENTIFIC OFFICER | FTax withholding Common Stock | -6,044 | $1.58 | $9,550 | 122,593 | Apr 2, 2025 |
| Mar 31, 2025 | Tyler Zeronda CHIEF FINANCIAL OFFICER | FTax withholding Common Stock | -8,399 | $1.58 | $13k | 118,493 | Apr 2, 2025 |
| Jan 21, 2025 | David Domzalski PRESIDENT AND CEO | AGrant or award Stock Option (right to buy)derivative | +730,000 | $0.00 | $0 | 730,000 | Jan 23, 2025 |
| Jan 21, 2025 | Mutya Harsch CHIEF LEGAL OFFICER AND GC | AGrant or award Stock Option (right to buy)derivative | +230,000 | $0.00 | $0 | 230,000 | Jan 23, 2025 |
| Jan 15, 2025 | Patrick G Lepore director | POpen-market purchase Common Stock | +15,000 | $2.92 | $44k | 51,472 | Jan 16, 2025 |
| Dec 31, 2024 | David Domzalski PRESIDENT AND CEO | FTax withholding Common Stock | -24,536 | $3.35 | $82k | 476,061 | Jan 2, 2025 |
| Dec 31, 2024 | Mutya Harsch CHIEF LEGAL OFFICER AND GC | FTax withholding Common Stock | -4,697 | $3.35 | $16k | 144,329 | Jan 2, 2025 |
| Dec 12, 2024 | Sharon Barbari director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 13, 2024 |
| Dec 12, 2024 | Steven L Basta director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 13, 2024 |
| Dec 12, 2024 | Christine Borowski director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 13, 2024 |
| Dec 12, 2024 | Anthony D Bruno director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 13, 2024 |
| Dec 12, 2024 | Patrick G Lepore director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 13, 2024 |
| Dec 12, 2024 | Elisabeth Sandoval Little director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Dec 13, 2024 |
| Nov 30, 2024 | David Domzalski PRESIDENT AND CEO | AGrant or award Common Stock | +3,901 | $2.10 | $8,192 | 500,597 | Dec 3, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sharon Barbaridirector
- Steven L Bastadirector, ceo, president, officer
- Christine Borowskidirector
- Anthony D Brunodirector
- David DomzalskiPRESIDENT AND CEO
- Mutya HarschCHIEF LEGAL OFFICER AND GC
- Patrick G Leporedirector
- Elisabeth Sandoval Littledirector
- Iain StuartCHIEF SCIENTIFIC OFFICER
- Tyler ZerondaCHIEF FINANCIAL OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.